CYP2D6 and female reproductive organ cancer: At present, paroxetine (Brisdelle, 7.5 mg) is the only antidepressant approved by the FDA for the treatment of moderate-to-severe VMS associated with menopause.175 Its efficacy has also been demonstrated in patients with breast and gynecological cancers.172,176 However, due to its strong inhibition of the cytochrome P450 2D6 (CYP2D6) enzyme, paroxetine should be avoided in patients on tamoxifen treatment.